High-risk prostate cancer (HR Pca) is a highly heterogeneous disease from a biological and clinical standpoint, and it carries a significant chance of morbidity and mortality. Despite the impact of PSA screening, a significant number of men continue to present with high risk disease and need adequate management: clinical evidence shows that a considerable fraction on men with HR PCa can be actually cured with either uni- or multi-modality approaches. Surgical treatment, once considered unfeasible in this setting, is acquiring more and more diffusion in modern clinical practice. Herein we discuss the main treatment strategies for high-risk prostate cancer, providing an expert opinion on the role of surgical management and its outcomes in the most recent literature.
Critical reviews in oncology/hematology. 2016 Apr 27 [Epub ahead of print]
Alessandro Morlacco, R Jeffrey Karnes
Urology Department, Mayo Clinic, Rochester, MN, USA; Department of Surgical, Oncological and Gastroenterological Sciences, Urology Clinic, University of Padova, Padova, Italy., Urology Department, Mayo Clinic, Rochester, MN, USA. Electronic address: .